Zoledronic acid and bone health in older adults with cognitive impairment.

ABSTRACT: Fracture prevention in cognitively impaired individuals is lacking. This work highlights the benefits of zoledronic acid on bone health in cognitively impaired older adults. Demonstrating benefits of therapy may increase treatment uptake and reduce fracture risk in this group.

Introduction

Osteoporosis has detrimental consequences for frail older adults. The effects on those with both osteoporosis and cognitive impairment are compounded due to increased risk of falls and changes in mobility, both of which can lead to fracture. However, there are limited data on treatment benefits for osteoporotic individuals with cognitive impairment.

Methods

This post hoc, secondary analysis of data from a randomized, double-blind, placebo-controlled clinical trial of single-dose zoledronic

SUBMITTER: Churilla BM 

PROVIDER: S-EPMC8758516 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature